Waeber, Baptiste, Bengt Kayser, Lionel Dumont, Christopher Lysakowski, Martin R. Tramèr, and Nadia Elia. Impact of study design on reported incidences of acute mountain sickness: A systematic review. High Alt Med Biol 16:204–215, 2015.—Aims: Published incidences of acute mountain sickness (AMS) vary widely. Reasons for this variation, and predictive factors of AMS, are not well understood. We aimed to identify predictive factors that are associated with the occurrence of AMS, and to test the hypothesis that study design is an independent predictive factor of AMS incidence. We did a systematic search (Medline, bibliographies) for relevant articles in English or French, up to April 28, 2013. Studies of any design reporting on AMS incidence in humans without prophylaxis were selected. Data on incidence and potential predictive factors were extracted by two reviewers and crosschecked by four reviewers. Associations between predictive factors and AMS incidence were sought through bivariate and multivariate analyses for different study designs separately. Association between AMS incidence and study design was assessed using multiple linear regression.
Results:
We extracted data from 53,603 subjects from 34 randomized controlled trials, 44 cohort studies, and 33 cross-sectional studies. In randomized trials, the median of AMS incidences without prophylaxis was 60% (range, 16%–100%); mode of ascent and population were significantly associated with AMS incidence. In cohort studies, the median of AMS incidences was 51% (0%–100%); geographical location was significantly associated with AMS incidence. In cross-sectional studies, the median of AMS incidences was 32% (0%–68%); mode of ascent and maximum altitude were significantly associated with AMS incidence. In a multivariate analysis, study design (p=0.012), mode of ascent (p=0.003), maximum altitude (p<0.001), population (p=0.002), and geographical location (p<0.001) were significantly associated with AMS incidence. Age, sex, speed of ascent, duration of exposure, or history of AMS were inconsistently reported and therefore not further analyzed.
Conclusions:
Reported incidences and identifiable predictive factors of AMS depend on study design.
Get full access to this article
View all access options for this article.
References
1.
AlizadehR, ZiaeeV, AghsaeifardZ, MehrabiF, and AhmadinejadT. (2012). Characteristics of headache at altitude among trekkers; A comparison between acute mountain sickness and non-acute mountain sickness headache. Asian J Sports Med, 3:126–130.
2.
AlizadehR, ZiaeeV, FrooghifardL-A, MansourniaM-A, and AghsaeifardZ. (2012). The effect of path and beginning time of ascending on incidence of acute mountain sickness around Mount Damavand in Iran (5671 m). Neurol Res Intl, 2012: 428296.
3.
AndersonPJ, MillerAD, O'MalleyKA, CeridonML, BeckKC, WoodCM, WisteHJ, MuellerJJ, JohnsonJB, and JohnsonBD. (2011). Incidence and symptoms of high altitude illness in South Pole workers: Antarctic Study of Altitude Physiology (ASAP). Clin Med Insights Circ Respir Pulm Med, 5:27–35.
4.
BaillieJK, ThompsonAAR, IrvingJB, BatesMGD, SutherlandAI, MacneeW, MaxwellSRJ, and WebbDJ. (2009). Oral antioxidant supplementation does not prevent acute mountain sickness: Double blind, randomized placebo-controlled Trial. QJM: Monthly J Assoc Phys, 102:341–348.
5.
BärtschP, and SwensonER. (2013). Clinical practice: Acute high-altitude illnesses. N Engl J Med, 368:2294–2302.
6.
BasnyatB, LemasterJ, and LitchJA. (1999). Everest or bust: A cross sectional, epidemiological study of acute mountain sickness at 4243 meters in the Himalayas. Aviat Space Environ Med, 70:867–873.
7.
BasnyatB, and LitchJA. (1997). Medical problems of porters and trekkers in the Nepal Himalaya. Wild Environ Med, 8:78–81.
8.
BasnyatB, SubediD, SleggsJ, LemasterJ, BhasyalG, AryalB, and SubediN. (2000). Disoriented and ataxic pilgrims: An epidemiological study of acute mountain sickness and high-altitude cerebral edema at a sacred lake at 4300 m in the Nepal Himalayas. Wild Environ Med, 11:89–93.
9.
BasnyatB, GertschJH, HolckPS, JohnsonEW, LuksAM, DonhamBP, FleischmanRJ, GowderDW, HawksworthJS, JensenBT, KleimanRJ, LoveridgeAH, LundeenEB, NewmanSL, BoboaJA, MiegsDP, O'BeirneKA, PhilpotKB, SchultzMN, ValenteMC, WiebersMR, and SwensonER. (2006). Acetazolamide 125 mg bd is not significantly different from 375 mg bd in the prevention of acute mountain sickness: The Prophylactic Acetazolamide Dosage Comparison for Efficacy (PACE) Trial. High Alt Med Biol, 7:17–27.
10.
BasnyatB, GertschJH, JohnsonEW, Castro-MarinF, InoueY, and YehC. (2003). Efficacy of low-dose acetazolamide (125 mg bid) for the prophylaxis of acute mountain sickness: A prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol, 4:45–52.
11.
BasnyatB, HargroveJ, HolckPS, SrivastavS, AlekhK, GhimireLV, PandeyK, GriffithsA, ShankarR, KaulK, PaudyalA, StasiukD, BasnyatR, DavisC, SouthardA, RobinsonC, ShandleyT, JohnsonDW, ZafrenK, WilliamsS, WeissEA, FarrarJJ, and SwensonER. (2008). Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Alt Med Biol, 9:209–216.
12.
BasnyatB, HolckPS, PunM, HalversonS, SzawarskiP, GertschJ, SteifM, PowellS, KhanalS, JoshiA, ShankarR, KarambayJ, AlexanderHD, StoneA, MorrisseyC, ThompsonBH, and FarrarJJ; SPACE Trial Group. (2011). Spironolactone does not prevent acute mountain sickness: A prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (Spironolactone and Acetazolamide Trial in the Prevention of Acute Mountain Sickness Group). Wilderness Environ Med, 22:15–22.
13.
BasnyatB, and MurdochDR. (2003). High-altitude illness. Lancet, 361:1967–1974.
14.
BatesM, ThompsonAAR, BaillieJK, SutherlandAI, IrvingJB, HiraniN, and WebbDJ. (2011). Sildenafil citrate for the prevention of high atitude hypoxic pulmonary hypertension: Double blind, randomized, placebo-controlled trial. High Alt Med Biol, 12:207–214.
15.
BeidlemanBA, FulcoCS, MuzaSR, RockPB, StaabJE, ForteVA, BrothersMD, and CymermanA. (2009). Effect of six days of staging on physiologic adjustments and acute mountain sickness during ascent to 4300 meters. High Alt Med Biol, 10:253–260.
16.
BeidlemanBA, MuzaSR, FulcoCS, RockPB, and CymermanA. (2007a). Validation of a shortened electronic version of the Environmental Symptoms Questionnaire. High Alt Med Biol, 8:192–199.
17.
BensonK, and HartzAJ. (2000). A comparison of observational studies and randomized, controlled trials. N Engl J Med, 342:1878–1886.
18.
BernhardWN, SchalickLM, and GittelsohnA. (1994). Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. J Wilderness Med, 5:331–338.
19.
BlochJ, DuplainH, RimoldiSF, StuberT, KriemlerS, AllemannY, SartoriC, and ScherrerU. (2009). Prevalence and time course of acute mountain sickness in older children and adolescents after rapid ascent to 3450 meters. Pediatrics, 123:1–5.
20.
BoschMM, BarthelmesD, MerzTM, BlochKE, TurkAJ, HeftiU, SutterFKP, MaggioriniM, WirthMG, SchochOD, and LandauK. (2008). High incidence of optic disc swelling at very high altitudes. Arch Ophthalmol, 126:644–650.
21.
BritoJ, SiquésP, León-VelardeF, De La CruzJJ, LópezV, and HerruzoR. (2007). Chronic intermittent hypoxia at high altitude exposure for over 12 years: Assessment of hematological, cardiovascular, and renal effects. High Alt Med Biol, 8:236–244.
22.
BurkiNK, KhanSA, and HameedMA. (1992). The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest, 101:736–741.
23.
BurseRL, CymermanA, and YoungAJ. (1987). Respiratory response and muscle function during isometric handgrip exercise at high altitude. Aviat Space Environ Med, 58:39–46.
24.
CarlstenC, SwensonER, and RuossS. (2004). A dose-response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Alt Med Biology, 5:33–39.
25.
CastellaniJW, MuzaSR, CheuvrontSN, SilsIV, FulcoCS, KenefickRW, BeidlemanBA, and SawkaMN. (2010). Effect of hypohydration and altitude exposure on aerobic exercise performance and acute mountain sickness. J Appl Physiol, 109:1792–1800.
26.
ChenGZ, QinJ, YuJ, GaoXB, DongJQ, LuW, BianSZ, ZengY, and HuangL. (2013). Incidence of acute mountain sickness in young adults at 3200 meters: Comparison of the Lake Louise Scoring and Chinese Scoring Systems. Genetics Mol Res, 12:6790–6801.
27.
ChenH-C, LinW-L, WuJ-Y, WangS-H, ChiuT-F, WengY-M, HsuT-Y, and WuM-H. (2012). Change in oxygen saturation does not predict acute mountain sickness on Jade Mountain. Wilderness Environ Med, 23:122–127.
28.
ChowT, BrowneV, HeilesonHL, WallaceD, AnholmJ, and GreenSM. (2005). Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: A randomized, placebo-controlled trial. Arch Int Med, 165:296–301.
29.
CymermanA, MuzaSR, BeidlemanBA, DitzlerDT, and FulcoCS. (2001). Postural instability and acute mountain sickness during exposure to 24 hours of simulated altitude (4300 m). High Alt Med Biol, 2:509–514.
30.
DallimoreJ, and RowbothamEC. (2009). Incidence of acute mountain sickness in adolescents. Wilderness Environ Med, 20:221–224.
31.
DaviesAJ, KalsonNS, StokesS, EarlMD, WhiteheadAG, FrostH, Tyrell-MarshI, and NaylorJ. (2009). Determinants of summiting success and acute mountain sickness on Mt Kilimanjaro (5895 m). Wilderness Environ Med, 20:311–317.
32.
DehnertC, WeymannJ, MontgomeryHE, WoodsD, MaggioriniM, ScherrerU, GibbsJSR, and BärtschP. (2002). No association between high-altitude tolerance and the ace i/d gene polymorphism. Med Sci Sports Exercise, 34:1928–1933.
33.
DellasantaP, GaillardS, LoutanL, and KayserB. (2007). Comparing questionnaires for the assessment of acute mountain sickness. High Alt Med Biol, 8:184–191.
34.
DiciannoBE, AguilaED, CooperRA, PasquinaPF, ClarkMJ, CollinsDM, FitzgeraldSG, and WichmanTA. (2008). Acute mountain sickness in disability and adaptive sports: Preliminary data. J Rehab Res Develop, 45:479–487.
35.
DouglasDJ, and SchoeneRB. (2010). End-tidal partial pressure of carbon dioxide and acute mountain sickness in the first 24 hours upon ascent to Cusco Peru (3326 meters). Wilderness Environ Med, 21:109–113.
36.
DubowitzG, and PeacockAJ. (2007). Pulmonary artery pressure in healthy subjects at 4250 m measured by Doppler echocardiography. Wilderness Environ Med, 18:305–311.
37.
DumontL, MardirosoffC, and TramèrMR. (2000). Efficacy and harm of pharmacological prevention of acute mountain sickness: Quantitative systematic review. BMJ (Clin Res Ed), 321:267–272.
38.
DumontL, LysakowskiC, TramèrMR, JunodJ-D, MardirosoffC, TassonyiE, and KayserB. (2004). Magnesium for the prevention and treatment of acute mountain sickness. Clin Sci (London, England: 1979), 106:269–277.
39.
EllsworthAJ, MeyerEF, and LarsonEB. (1991). Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med, 154:289–293.
40.
EllsworthAJ, LarsonEB, and StricklandD. (1987). A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am J Med, 83:1024–1030.
41.
ErbaP, AnastasiS, SennO, MaggiorirniM, and BlochKE. (2004). Acute mountain sickness is related to nocturnal hypoxemia but not to hypoventilation. Eur Respir J, 24:303–308.
42.
FischerR, VollmarC, ThiereM, BornC, LeitlM, PflugerT, and HuberR. (2004). No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia, 24:66–71.
43.
GaillardS, DellasantaP, LoutanL, and KayserB. (2004). Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal: A 12-year follow-up. High Alt Med Biology, 5:410–419.
44.
GertschJH, BasnyatB, JohnsonEW, OnopaJ, and HolckPS. (2004). Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among himalayan trekkers: The Prevention of High Altitude Illness Trial (PHAIT). BMJ (Clin Res Ed), 328:797.
45.
GertschJH, CorbettB, HolckPS, MulcahyA, WattsM, StillwagonNT, CastoAM, AbramsonCH, VaughanCP, MacguireC, FarzanNN, VoBN, NorvelleRJ, MayK, HollyJE, IronsH, StutzAM, ChapagainP, YadavS, PunM, FarrarJ, and BasnyatB. (2012). Altitude sickness in climbers and efficacy of NSAIDs Trial (ASCENT): Randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness Environ Med, 23:307–315.
46.
GertschJH, LipmanGS, HolckPS, MerrittA, MulcahyA, FisherRS, BasnyatB, AllisonE, HanzelkaK, HazanA, MeyersZ, OdegaardJ, PookB, ThompsonM, SlomovicB, WahlbergH, WilshawV, WeissEA, and ZafrenK. (2010). Prospective, Double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: The Headache Evaluation at Altitude Trial (HEAT). Wilderness Environ Med, 21:236–243.
47.
GertschJH, SetoTB, MorJ, and OnopaJ. (2002). Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt Med Biol, 3:29–37.
48.
GrissomCK, RicherLD, and ElstadMR. (2005). The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude. Chest, 127:565–570.
49.
HackettPH, RennieD, and LevineHD. (1976). The incidence, importance, and prophylaxis of acute mountain sickness. Lancet, 2:1149—1155.
50.
HackettPH, and RoachRC. (2001). High-altitude illness. N Engl J Med, 345:107–114. d
51.
HillenbrandP, PahariAK, SoonY, SubediD, BajracharyaR, GurungP, LalBK, MarahattaR, PradhanS, RaiD, and SharmaS; Birmingham Medical Research Expeditionary Society. (2006). Prevention of acute mountain sickness by acetazolamide in Nepali porters: A double-blind controlled trial. Wilderness Environ Med, 17:87–93.
52.
HonigmanB, ReadM, LezotteD, and RoachRC. (1995). Sea-level physical activity and acute mountain sickness at moderate altitude. West J Med, 163:117–121.
53.
HonigmanB, TheisMK, Koziol-McLainJ, RoachR, YipR, HoustonC, MooreLG, and PearceP. (1993). Acute mountain sickness in a general tourist population at moderate altitudes. Ann Int Med, 118:587–592.
54.
HooperTJ, LevettDZH, MellorAJ, and GrocottMPW. (2010). Resting and exercising cardiorespiratory variables and acute mountain sickness. J Royal Naval Med Serv, 96:6–12.
55.
ImrayC, WrightA, SubudhiA, and RoachR. (2010). Acute mountain sickness: pathophysiology, prevention, and treatment. Prog Cardiovasc Dis, 52:467–484.
56.
ImrayCHE, KennedyCH, PattinsonK, BreareyS, and WrightA. (2004). Self-assessment of acute mountain sickness in adolescents: A pilot study. Wilderness Environ Med, 15:202–206.
57.
JacksonSJ, VarleyJ, SellersC, JosephsK, CodringtonL, DukeG, NjelekelaMA, DrummondG, SutherlandAI, ThompsonAA, and BaillieJK. (2010).Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro. High Alt Med Biol, 11:217–222.
58.
JafarianS, GorouhiF, and LotfiJ. (2007). Reverse association between high-altitude headache and nasal congestion. Cephalalgia, 27:899–903.
59.
JafarianS, GorouhiF, SalimiS, and LotfiJ. (2007).Sumatriptan for prevention of acute mountain sickness: Randomized clinical trial. Ann Neurol, 62:273–277.
60.
JafarianS, GorouhiF, TaghvaA, and LotfiJ. (2008). High-altitude sleep disturbance: Results of the Groningen Sleep Quality Questionnaire Survey. Sleep Med, 9:446–449.
61.
JohnsonPL, PopaDA, PriskGK, EdwardsN, and SullivanCE. (2010). Non-Invasive positive pressure ventilation during sleep at 3800 m: Relationship to acute mountain sickness and sleeping oxyhaemoglobin saturation. Respirology (Carlton, Vic.), 15:277–282.
62.
KamatSR, and BanerjiBC. (1972). Study of cardiopulmonary function on exposure to high altitude. I. Acute acclimatization to an altitude of 3,5000 to 4,000 meters in relation to altitude sickness and cardiopulmonary function. Am Rev Respirat Dis, 106: 404–413.
63.
KaoW-F, KuoCC, HsuT-F, ChangH, SungY-Y, YenDHT, WuJ-K, and LeeC-H. (2002). Acute mountain sickness in Jade Mountain climbers of Taiwan. Aviat Space Environ Med, 73:359–362.
64.
KarinenH, PeltonenJ, and TikkanenH. (2008). Prevalence of acute mountain sickness among Finnish trekkers on Mount Kilimanjaro, Tanzania: An observational study. High Alt Med Biology, 9:301–306.
65.
KayserB, AlivertiA, PellegrinoR, DellacaR, QuarantaM, PompilioP, MiserocchiG, and CogoA. (2010).Comparison of a Visual Analogue Scale and Lake Louise Symptom Scores for acute mountain sickness. High Alt Med Biol, 11:69–72.
66.
KayserB, DumontL, LysakowskiC, CombescureC, HallerG, and TramèrMR. (2012). Reappraisal of acetazolamide for the prevention of acute mountain sickness: A systematic review and meta-analysis. High Alt Med Biol, 13:82–92.
67.
KayserB, HulseboschR, and BoschF. (2008). Low-dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Alt Med Biol, 9: 15–23.
68.
KronenbergRS, and CainSM. (1967). Hastening respiratory acclimatization to altitude with benzolamide. In: Biomedical Problems of High Terrestrial Elevations, edited by HegnauerA.H., Springfield, VA: Clearing House Fed Sci Tech Info. pp. 57–63.
69.
KüpperTEAH, StrohlKP, HoeferM, GieselerU, NetzerCM, and NetzerNC. (2008). Low-dose theophylline reduces symptoms of acute mountain sickness. J Travel Med, 15:307–314.
70.
LalandeS, AndersonPJ, MillerAD, CeridonML, BeckKC, O'MalleyKA, JohnsonJB, and JohnsonBD. (2011). Variability in pulmonary function following rapid altitude ascent to the Amundsen-Scott South Pole Station. Eur J Appl Physiol, 111:2221–2228.
71.
LarsonEB, RoachRC, SchoeneRB, and HornbeinTF. (1982). Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA, 288:328–332.
72.
LeadbetterG, KeyesLE, MaakestadKM, OlsonS, Tissot van PatotMC, and HackettPH. (2009). Ginkgo biloba does—and does not—prevent acute mountain sickness. Wilderness Environ Med, 20:66–71.
73.
LiF-X, JiF-Y, ZhengS-Z, YaoW, XiaoZ-L, and QianG-S. (2011). MtDNA haplogroups M7 and B in Southwestern Han Chinese at risk for acute mountain sickness. Mitochondrion, 11:553–558.
74.
LiX, TaoF, PeiT, YouH, LiuY, and GaoY. (2011a). Population level determinants of acute mountain sickness among young men: A retrospective study. BMC Public Health, 11:740.
75.
LiX, TaoF, YouH, PeiT, and GaoY. (2011b). Factors associated with acute mountain sickness in young Chinese men on entering highland areas. Asia Pac J Public Health. 2015Mar; 27(2):NP116–31. doi: 10.1177/1010539511427956. Epub 2011Dec20.
76.
LipmanGS, KanaanNC, HolckPS, ConstanceBB, GertschJH, and PAINS Group. (2012). Ibuprofen prevents altitude illness: A randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories. Ann Emerg Med, 59:484–490.
77.
LyonsTP, MuzaSR, RockPB, and CymermanA. (1995). The effect of altitude pre-acclimatization on acute mountain sickness during reexposure. Aviat Space Environ Med, 66:957–962.
78.
MacInnisMJ, LohseKR, StrongJK, and KoehleMS. (2013).Is previous history a reliable predictor for acute mountain sickness susceptibility? A meta-analysis of diagnostic accuracy. Br J Sports Med, 14:334–337.
79.
MacInnisMJ, KoehleMS, and RupertJL. (2010). Evidence for a genetic basis for altitude illness: 2010 update. High Alt Med Biol, 11:349–368.
80.
MaggioriniM, BühlerB, WalterM, and OelzO. (1990). Prevalence of acute mountain sickness in the Swiss Alps. BMJ (Clin Res Ed.), 301:853–855.
81.
MaggioriniM, MüllerA, HofstetterD, BärtschP, and OelzO. (1998). Assessment of acute mountain sickness by different score protocols in the Swiss Alps. Aviat Space Environ Med, 69:1186–1192.
82.
MaggioriniM, Brunner-La RoccaH-P, PethS, FischlerM, BöhmT, BernheimA, KienckeS, BlochKE, DehnertC, NaeijeR, LehmannT, BartschP, and MairbaurlH. (2006). Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: A randomized trial. Ann Int Med, 145:497–506.
83.
MairerK, WilleM, BucherT, and BurtscherM. (2009). Prevalence of acute mountain sickness in the Eastern Alps. High Alt Med Biol, 10:239–245.
84.
MairerK, WilleM, and BurtscherM. (2010).The prevalence of and risk factors for acute mountain sickness in the Eastern and Western Alps. High Alt Med Biol, 11:343–348.
85.
MeyerJ. (2012). Twice-daily assessment of trekkers on Kilimanjaro's Machame route to evaluate the incidence and time-course of acute mountain sickness. High Alt Med Biol, 13:281–284.
86.
MistryG, ChandrashekharY, SenU, and AnandIS. (1993). Study of acute mountain sickness during ‘rapid ascent’ trekking to extreme altitude. J Assoc Physicians India, 41:500–502.
87.
MontgomeryAB, LuceJM, MichaelP, and MillsJ. (1989). Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA: 261:734–736.
88.
MoragaFA, FloresA, SerraJ, EsnaolaC, and BarrientoC. (2007). Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern Chile. Wilderness Environ Med, 18:251–257.
89.
MoragaFA, OsorioJD, and VargasME. (2002). Acute mountain sickness in tourists with children at Lake Chungará (4400 m) in northern Chile. Wilderness Environ Med, 13:31–35.
90.
MoragaFA, PedrerosCP, and RodríguezCE. (2008). Acute mountain sickness in children and their parents after rapid ascent to 3500 m (Putre, Chile). Wilderness Environ Med, 19:287–292.
91.
MurdochDR. (1995). Symptoms of infection and altitude illness among hikers in the Mount Everest Region of Nepal. Aviat Space Environ Med, 66:148–151.
92.
MurdochDR, and CurryC. (1998). Acute mountain sickness in the southern Alps of New Zealand. N Zealand Med J, 111:168–169.
93.
MuzaSR, KaminskyD, FulcoCS, BanderetLE, and CymermanA. (2004). Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviat Space Environ Med, 75:413–419.
94.
MyersSD, BiccardBM, ChanC, ImrayCHE, WrightAD, PattinsonKTS, and Birmingham Medical Research Expeditionary Society. (2008). Delayed acclimatization of the ventilatory threshold in healthy trekkers. Wilderness Environ Med, 19:124–128.
NewcombL, SherpaC, NickolA, and WindsorJ. (2011).A comparison of the incidence and understanding of altitude illness between porters and trekkers in the Solu Khumbu Region of Nepal. Wilderness Environ Med, 22:197–201.
97.
PesceC, LealC, PintoH, GonzálezG, MaggioriniM, SchneiderM, and BärtschP. (2005).Determinants of acute mountain sickness and success on Mount Aconcagua (6962 m). High Alt Med Biol, 6:158–166.
98.
PradhanS, YadavS, NeupaneP, and SubediP. (2009). Acute mountain sickness in children at 4380 meters in the Himalayas. Wilderness Environ Med, 20:359–363.
99.
RegardM, LandisT, CaseyJ, MaggioriniM, BärtschP, and OelzO. (1991). Cognitive changes at high altitude in healthy climbers and in climbers developing acute mountain sickness. Aviat Space Environ Med, 62:291–295.
100.
RenY, FuZ, ShenW, JiangP, HeY, PengS, WuZ, and CuiB. (2010). Incidence of high altitude illnesses among unacclimatized persons who acutely ascended to Tibet. High Alt Med Biol, 11:39–42.
101.
RexhajE, GarcinS, RimoldiSF, DuplainH, StuberT, AllemannY, SartoriC, and ScherrerU. (2011). Reproducibility of acute mountain sickness in children and adults: A prospective study. Pediatrics, 127:e1445–1448.
102.
RichaletJP, DonosoMV, JiménezD, AntezanaA-M, HudsonC, CortèsG, OsorioJ, and LeònA. (2002). Chilean miners commuting from sea level to 4500 m: A prospective study. High Alt Med Biol, 3:159–166.
103.
RoachRC, HoustonCS, HonigmanB, NicholasRA, YaronM, GrissomCK, AlexanderJK, and HultgrenHN. (1995). How well do older persons tolerate moderate altitude?. West J Med, 162:32–36.
104.
RoachRC, LarsonEB, HornbeinTF, HoustonCS, BartlettS, HardestyJ, JohnsonD, and PerkinsM. (1983). Acute mountain sickness, antacids and ventilation during rapid, active ascent of Mount Rainier. Aviat Space Environ Med, 54:397–401.
105.
RoachRC, BärtschP, and OelzO. (1993). Lake Louise AMS Scoring Consensus Commitee: The Lake Louise Acute Mountain Sickness Scoring System. In: Hypoxia and Molecular Medicine: Proceedings of the 8th International Hypoxia Symposium Held at Lake Louise, Canada, February 9–13, 1993, by SuttonJohn R., HoustonCharles S., and CoatesGeoff, Burlington, VT: Queen City Printers. pp. 272–274.
106.
RoachR, and KayserB. (2007). Measuring mountain maladies. High Alt Med Biol, 8: 171–172.
107.
RockPB, JohnsonTS, LarsenRF, FulcoCS, TradLA, and CymermanA. (1989). Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest, 95:568–573.
108.
RockPB, JohnsonTS, CymermanA, BurseRL, FalkLJ, and FulcoCS. (1987). Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviat Space Environ Med, 58:668–672.
109.
RoegglaG, RoegglaM, PodolskyA, WagnerA, and LaggnerAN. (1996). How can acute mountain sickness be quantified at moderate altitude?. J Royal Soc Med, 89:141–143.
110.
RögglaG, WagnerA, and RögglaM. (1992). Is the incidence of acute mountain sickness (AMS) at medium altitude in the Austrian Alps influenced by the height of home residence of the alpinist?. Acta Medica Hungarica, 49:233–238.
111.
SalazarH, SwansonJ, MozoK, WhiteACJr, and CabadaMM. (2012). Acute mountain sickness impact among travelers to Cusco, Peru. J Travel Med, 19:220–225.
112.
SchneiderM, BernaschD, WeymannJ, HolleR, and Bartsch. (2002). Acute mountain sickness: Influence of susceptibility, preexposure, and ascent rate. Med Sci Sports Exercise, 34:1886–1891.
113.
ShahMB, BraudeD, CrandallCS, KwackH, RabinowitzL, CumboTA, BasnyatB, and BhasyalG. (2006). Changes in metabolic and hematologic laboratory values with ascent to altitude and the development of acute mountain sickness in Nepalese pilgrims. Wilderness Environ Med, 17:171–177.
114.
SilberE, SonnenbergP, CollierDJ, PollardAJ, MurdochDR, and GoadsbyPJ. (2003). Clinical features of headache at altitude: A prospective study. Neurology, 60:1167–1171.
115.
StokesS, KalsonNS, EarlM, WhiteheadAG, Tyrrell-MarshI, FrostH, and DaviesA. (2010). Age is no barrier to success at very high altitudes. Age Ageing, 39:262–265.
116.
SubudhiAW, PaneraiRB, and RoachRC. (2010). Effects of hypobaric hypoxia on cerebral autoregulation. Stroke, 41:64646.
117.
TalbotNP, SmithTG, PrivatC, NickolAH, Rivera-ChM, León-VelardeF, DorringtonKL, and RobbinsPA. (2011). Intravenous iron supplementation may protect against acute mountain sickness: A randomized, double-blinded, placebo-controlled trial. High Alt Med Biol, 12:265–269.
118.
TalbotTS, TownesDA, and WedmoreIS. (2004). To air is human: Altitude illness during an expedition length adventure race. Wilderness Environ Med, 15:90–94.
119.
TangE, ChenY, and LuoY. (2014). Dexamethasone for the prevention of acute mountain sickness: Systematic review and meta-analysis. Intl J Cardiol, 173:133–138.
120.
TheisMK, HonigmanB, YipR, McBrideD, HoustonCS, and MooreLG. (1993). Acute mountain sickness in children at 2835 meters. Am J Dis Children (1960), 147:143–145.
121.
Tissot van PatotMC, LeadbetterG, KeyesLE, Bendrick-PeartJ, BeckeyVE, ChristiansU, and HackettP. (2005). Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness. J Appl Physiol (Bethesda, Md.: 1985), 98:1626–1629.
122.
Tissot Van PatotMC, LeadbetterG, KeyesLE, MaakestadKM, OlsonS, and HackettPH. (2008). Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt Med Biol, 9:289–293.
123.
TsianosG, Woolrich-BurtL, AitchisonT, PeacockA, WattM, MontgomeryH, WattI, and GrantS. (2006). Factors affecting a climber's ability to ascend Mont Blanc. Eur J Appl Physiol, 96:32–36.
124.
UtzG, Schlierf, Barth, Linhart, and Wollenweber. (1970). [Prevention of acute mountain sickness using acetazolamide]. Münchener Med Wochenschrift (1950), 112:1122–1124.
125.
VardyJ, VardyJ, and JudgeK. (2006). Acute mountain sickness and ascent rates in trekkers above 2500 m in the Nepali Himalaya. Aviat Space Environ Med, 77:742–744.
126.
WagnerDR, D'ZatkoK, TatsugawaK, MurrayK, ParkerD, StreeperT, and WillardK. (2008). Mt. Whitney: Determinants of summit success and acute mountain sickness. Med Sci Sports Exercise, 40:1820–1827.
127.
WagnerDR, FargoJD, ParkerD, TatsugawaK, and YoungTA. (2006). Variables contributing to acute mountain sickness on the summit of Mt Whitney. Wilderness Environ Med, 17:221–228.
128.
WagnerDR, TeramotoM, KnottJR, and FryJP. (2012). Comparison of scoring systems for assessment of acute mountain sickness. High Alt Med Biol, 13:245–251.
129.
WangJ, KeT, ZhangX, ChenY, LiuM, ChenJ, and LuoW. (2013). Effects of acetazolamide on cognitive performance during high-altitude exposure. Neurotoxicol Teratol, 35:28–33.
130.
WangS-H, ChenY-C, KaoW-F, LinY-J, ChenJ-C, ChiuT-F, HsuT-Y, ChenH-C, and LiuS-W. (2010). Epidemiology of acute mountain sickness on Jade Mountain, Taiwan: An annual prospective observational study. High Alt Med Biology, 11:43–49.
131.
WestJB, SchoeneRB, LuksA, and MilledgeJS. (2013). High Altitude Medicine and Physiology., 5th ed. Boca Raton; London: CRC Press.
132.
WillmannG, FischerMD, SchatzA, SchommerK, MessiasA, ZrennerE, Bartz-SchmidtKU, and GekelerF. (2011). Quantification of optic disc edema during exposure to high altitude shows no correlation to acute mountain sickness. PloS One, 6:e27022.
133.
WuTY, DingSQ, LiuJL, YuMT, JiaJH, DuanJQ, ChaiCZ, DaiRC, ZhangSL, LiangBZ, ZhaoJZ, QiDT, SunYF, and KayserB. (2009). Reduced incidence and severity of acute mountain sickness in Qinghai-Tibet railroad construction workers after repeated 7-month exposures despite 5-month low altitude periods. High Alt Med Biol, 10:221–232.
134.
WuTY, DingSQ, LiuJL, YuMT, JiaJH, ChaiZC, DaiRC, ZhangSL, LiBY, PanL, LiangBZ, ZhaoJZ, QiDT, SunYF, and KayserB. (2007). Who should not go high: Chronic disease and work at altitude during construction of the Qinghai-Tibet Railroad. High Alt Med Biol, 8:88–107.
135.
WuTY, DingSQ, LiuJL, JiaJH, ChaiZC, and DaiRC. (2012). Who are more at risk for acute mountain sickness: A prospective study in Qinghai-Tibet railroad construction workers on Mt. Tanggula. Chin Med J, 125:1393–1400.
136.
WuTY, DingSQ, LiuJL, JiaJH, ChaiZC, Dai RCJZ, TangQD, and KayserB. (2012).Smoking, acute mountain sickness and altitude acclimatisation: A cohort study. Thorax, 67:914–919.
137.
YaronM, WaldmanN, NiermeyerS, NicholasR, and HonigmanB. (1998). The diagnosis of acute mountain sickness in preverbal children. Arch Pediatr Adolesc Med, 152:683–687.
138.
YaronM, NiermeyerS, LindgrenKN, and HonigmanB. (2002). Evaluation of diagnostic criteria and incidence of acute mountain sickness in preverbal children. Wilderness Environ Med, 13:21–26.
139.
ZellSC, and GoodmanPH. (1988). Acetazolamide and dexamethasone in the prevention of acute mountain sickness. West J Med, 148:541–545.
140.
ZiaeeV, YunesianM, AhmadinejadZ, HalabchiF, KordiR, AlizadehR, and AfsharjooHR. (2003). Acute mountain sickness in Iranian trekkers around Mount Damavand (5671 m) in Iran. Wilderness Environ Med, 14:214–219.
